# Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML

> **NCT07539818** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 788 (estimated)

## Conditions studied

- AML

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT07539818
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-29
- **Primary completion:** 2030-04-01
- **Final completion:** 2031-04-01
- **Target enrollment:** 788 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07539818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07539818, "Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07539818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*